FDA Expands Approval of Jardiance for Patients With Heart Failure
MONDAY, Feb. 28, 2022 -- Approval for Jardiance (empagliflozin) has been expanded to reduce the risk for cardiovascular death and hospitalization for heart failure in adults, the U.S. Food and Drug Administration announced Thursday.
Jardiance...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
More News: Cardiology | Cardiovascular | Empagliflozin | Food and Drug Administration (FDA) | Heart | Heart Failure | Jardiance | Pharmaceuticals